Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies (NCT02702102) | Clinical Trial Compass
CompletedPhase 2
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
United States5 participantsStarted 2015-12
Plain-language summary
This study uses a special type of scan called a positron emission tomography (PET) scan to take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected into the body.
11C-PBR28 sticks to parts of the brain where there is inflammation. The purpose of this study is to see if 11C-PBR28 can detect inflammation in patients with Parkinson's disease dementia or dementia with Lewy bodies.
11C-PBR28 is considered a drug by the Food and Drug Administration. 11C-PBR28 is not a treatment for any disease. Rather, 11C-PBR28 can be used to measure inflammation in the brain.
Who can participate
Age range60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Age 60 and older.
ā. Meet criteria for either a) dementia with Lewy bodies, or b) Parkinson's disease dementia.
ā. Written and oral fluency in English.
ā. Able to participate in all scheduled evaluations and to complete all required tests and procedures.
ā. In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.
ā. Age 60 and older.
ā. Normal cognitive and motor function based on neurological examination.
ā. Written and oral fluency in English.
Exclusion criteria
ā. Past or present history of certain other brain disorders.
ā. Certain significant medical conditions. Examples are uncontrolled epilepsy or multiple serious injuries.
What they're measuring
1
Absolute 11C-PBR28 Binding (Total Distribution Volume Corrected for Free Fraction in Plasma)